BioSymetrics
BioSymetrics, a subsidiary of Lunai Bioworks (NASDAQ: LNAI), operates at the intersection of AI-driven drug discovery and phenotypic screening.
Profile
AI-driven drug discovery platform combining machine learning and zebrafish-based phenotypic screening to identify therapeutic targets.
BioSymetrics, a subsidiary of Lunai Bioworks (NASDAQ: LNAI), operates at the intersection of AI-driven drug discovery and phenotypic screening. Founded to address the high failure rates in clinical trials—90% of which fail due to lack of efficacy—the company integrates machine learning with in vivo validation using zebrafish models to identify and validate therapeutic targets. Its platform combines high-throughput phenotypic screening with AI-driven mechanism-of-action prediction, aiming to accelerate drug discovery for central nervous system (CNS) diseases and oncology.
Recent moves include a $20M strategic acquisition by Lunai Bioworks in March 2026, which expanded its capabilities in blood-brain barrier delivery for CNS therapies. BioSymetrics has also secured defense contracts for chemical threat assessment, leveraging its AI platform to screen neuroactive compounds. The company collaborates with academic and defense partners, including a national consortium targeting $400M-$1.2B U.S. countermeasure programs. Financials are consolidated under Lunai Bioworks, which reported $20M in strategic transactions in 2026.
Who buys this
- Pharmaceutical companies developing CNS and oncology therapies
- Defense and biodefense agencies screening chemical threats
- Academic research institutions studying disease mechanisms
- Biotech firms outsourcing target discovery and validation
Strengths and what to watch
Strengths
- Proprietary AI platform integrating phenotypic screening and machine learning for rapid target identification
- Validated in vivo zebrafish models for high-throughput compound testing
- Dual-use applications in drug discovery and defense, diversifying revenue streams
Watch for
- Dependence on parent company Lunai Bioworks for funding and strategic direction
- High competition in AI-driven drug discovery from well-funded rivals
- Regulatory risks in defense contracts and drug development timelines
Recent moves
- 5mo ago BioSymetrics and BrainStorm Therapeutics launch foundation-funded Parkinson's and rare epilepsy AI discovery collaboration
- 6mo ago Lunai Bioworks secures first revenue-generating defense collaboration through BioSymetrics for chemical threat assessment
- 7mo ago Lunai Bioworks launches national chemical defense consortium targeting $400M-$1.2B U.S. countermeasure programs
Key Information
- Founded
- 2017
- Headquarters
- New York
Frequently Asked Questions
What does BioSymetrics do in drug discovery?
BioSymetrics combines AI-driven machine learning with zebrafish phenotypic screening to identify therapeutic targets. Their platform accelerates drug discovery for CNS diseases and oncology by predicting mechanisms of action and validating compounds in vivo, addressing high clinical trial failure rates.
How does zebrafish screening improve drug discovery?
Zebrafish models enable high-throughput in vivo testing of compounds, providing rapid biological validation. BioSymetrics integrates this with AI to analyze phenotypic changes, improving target identification accuracy while reducing reliance on less predictive in vitro methods.
What diseases does BioSymetrics focus on?
The company primarily targets central nervous system disorders and oncology. Their 2026 acquisition expanded capabilities in blood-brain barrier delivery for CNS therapies, while defense contracts apply their platform to neuroactive compound screening for chemical threats.
Who uses BioSymetrics' technology?
Pharmaceutical firms, biotech companies, and academic researchers leverage their platform for target discovery. Defense agencies also use it for chemical threat assessment, creating dual revenue streams from therapeutic and national security applications.
What recent partnerships has BioSymetrics announced?
In 2026, BioSymetrics partnered with BrainStorm Therapeutics for Parkinson's and epilepsy research, secured defense contracts for chemical threat screening, and joined a $400M-$1.2B national consortium developing AI-driven countermeasures.
Is BioSymetrics publicly traded?
BioSymetrics operates as a subsidiary of Lunai Bioworks (NASDAQ: LNAI), which acquired it in a $20M strategic transaction. Financials are consolidated under Lunai, which reported $20M in strategic deals involving BioSymetrics' technology in 2026.
Sources
- www.prnewswire.com — $20M strategic acquisition by Lunai Bioworks
- www.prnewswire.com — Collaboration with BrainStorm Therapeutics
- www.prnewswire.com — Defense collaboration for chemical threat assessment
- www.prnewswire.com — National chemical defense consortium targeting $400M-$1.2B programs